Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.23 USD | +1.38% | +0.13% | +33.12% |
05-09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
05-08 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.12% | 6.22B | |
+50.07% | 56.69B | |
-2.98% | 41B | |
+38.14% | 38.11B | |
-11.22% | 26.89B | |
+15.10% | 25.59B | |
-22.57% | 18.59B | |
+0.25% | 12.39B | |
+26.81% | 11.99B | |
+22.86% | 11.88B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Transcript : Revolution Medicines, Inc., Q3 2022 Earnings Call, Nov 07, 2022